Domain editor

Largest Genes2Me IVD Kit Manufacturer Redefines RTPCR Test Kit Realm with 40 Minute No Extraction RT-PCR Test Kit

Genes2Me, a leading IVD manufacturer and genetic diagnostic company, recently launched its brand new RT-Direct Multiplex RTPCR kit for COVID-19.

The first product of its kind “Made in India”, this kit is based on the Gold Standard RTPCR method with a coverage of 3 target genes specific to SARS-COV-2 with IC, which is much more advanced than all the others having 1 or 2 target genes.

This greatly increases the sensitivity of the RTPCR assay to detect samples with different mutations / variants because this kit targets 3 different Sars-cov-2 target regions.

Validated in an ICMR approved center with 100% sensitivity and specificity, this newly launched kit can deliver results in just 40 minutes. The RT-Direct assay protocol does not require any manual extraction step or automated instrumentation, making it faster and easier to deliver results. It will also increase the throughput of any test lab by 3 times over the normal RTPCR test protocol time of 120 to 150 minutes. The Company has also received DCGI approval for this Kit.

While discussing the benefits of the new product, Neeraj Gupta, Founder and CEO of Genes2Me said, “The RNA extraction process has so far been a critical step in the RT PCR test protocol for COVID-19 which affects report time, results and cost. Our recently launched RTPCR kit will not only reduce the turnaround time by 3 times, but also save huge costs in extraction kit and machine, which would eventually make COVID testing more affordable in our country. In addition, he added that the company has innovated the proprietary enzyme to be one of the fastest and most efficient in the world, which helps cut RTPCR time in half compared to other standard enzymes used in all other kits. This is the main reason why we are able to reduce the reaction time in 40 minutes with 100% sensitivity.

“With the use of our RT-Direct Multiplex RTPCR kit for COVID-19, all diagnostic entities will be able to provide the results as soon as possible. Thus, in the event of a next COVID wave, the kit will help reduce the burden on the diagnostic industry by providing fast and accurate results. The test kit is also compatible with RT PCR devices commonly available in the market, “he added.

Since the start of the pandemic, Genes2Me has offered a variety of innovative solutions to meet the challenge posed by COVID-19. Genes2Me has embarked on manufacturing the highest quality ICMR validated and CE-IVD certified IVD molecular kits for COVID-19 testing. It is now established as one of the leading manufacturers of IVD kits for COVID-19 testing and has provided over 50 million tests to date.

These advanced kits will be immediately applied in many laboratories across the country, including Genes2Me’s own clinical diagnostic laboratory. We will be able to report patient samples in less than 60 minutes. The kit is now readily available in India from the second week of November 2021 and for the international market it will be available following a global launch at Medica event on November 15 in Messe Dusseldorf, Germany.

Founded in 2016 by Neeraj Gupta and Ritu Gupta, Genes2Me is a genomics-focused diagnostics company with the goal of continuously developing unique and innovative IVD genetic solutions to improve global health, even in resource-constrained areas. Through its wide range of genetic testing, Genes2Me has helped clinicians and individuals across India understand complex genetic disorders and susceptibility to various health issues. The company has been able to provide innovative genetic testing solutions as an IVD kit manufacturer and also provide genetic testing services in the segments of personalized health, maternal and child care, oncology and Infectious diseases.

This story is provided by NewsView. will in no way be responsible for the content of this article. (ANI / NewsView)

(With entries from ANI)

Disclaimer: This article was posted automatically from an agency feed without any text changes and has not been reviewed by an editor

Open in app